Approximately what percentage of subjects in the "Provide-injected DMPA-IM" group were still using contraceptives at 360 days of follow-up? 36% 100% 0% 64%
The following abstract portion is taken from a 2018 article published in Contraception.
Objective: The purpose of this study was to compare 12-month continuation rates for subcutaneous depot medroxyprogesterone acetate (DMPA-SC) administered via self-injection and DMPA-IM administered by a health worker in Uganda.
Study design: Women seeking injectable contraception at participating health facilities were offered the choice of self-injecting DMPA-SC or receiving an injection of DMPA-IM from a health worker. Those opting for self-injection were trained one-on-one. They self-injected under supervision and took home three units, a client instruction guide and a re-injection calendar. Those opting for DMPA-IM received an injection and an appointment card for the next facility visit in 3 months. We interviewed participants at baseline (first injection) and after 3 (second injection), 6 (third injection) and 9 (fourth injection) months, or upon discontinuation. We used Kaplan–Meier methods to estimate continuation probabilities.
The following graphic shows the estimated Kaplan-Meier curves tracking contraception discontinuation for both groups (these curves track the proportion of subjects who have not discontinued contraception usage over the follow-up period).
Trending now
This is a popular solution!
Step by step
Solved in 2 steps with 2 images
